Dr. Flaherty is a Professor of Medicine at Harvard Medical School and Director of Clinical Research, at the Massachusetts General Hospital Cancer Center. He co-founded and served on the Board of Directors of Loxo Oncology until its acquisition by Eli Lilly and Company. He currently serves on the Board of Directors of Clovis Oncology and Checkmate Pharmaceuticals. Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1 and PO1 grants. He is an author of many research articles, abstracts and reviews in the peer-reviewed literature, including three first-author and three senior author New England Journal of Medicine papers. He serves as Editor-in-Chief for Clinical Cancer Research and on the Board of Directors of the American Association for Cancer Research. Dr. Flaherty holds a B.S. from Yale University and an M.D. from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.
